抗NMDA受体脑炎患者的长期残疾、认知障碍和情绪症状
这项单中心回顾性观察研究纳入38例脑脊液NMDA受体IgG阳性的成人患者,用mRS和CASE评估短期和长期结局。尽管mRS和CASE从基线到长期随访均有改善,但仅9例(31%)恢复至病前功能,认知和情绪评估中中重度认知障碍、抑郁和焦虑仍常见,提示常用结局量表未全面反映长期功能损害。
要点
- 抗NMDA受体脑炎患者长期随访中仅31%恢复至病前功能,mRS和CASE改善但未捕捉认知与情绪损害。
- 起病时乏力是唯一预测长期mRS较高的因素(OR=5.6,95%CI 1.02-30.9,p=0.047)。
- 超过6个月评估的患者中,中重度认知障碍42%、抑郁28%、焦虑30%仍常见。
核心结论
- 尽管多数患者mRS和CASE随时间改善,但这些量表未全面反映情绪、认知及恢复至病前功能方面的长期损害,强调需更多使用细致的认知和情绪结局量表。
研究设计与样本
- 单中心、回顾性、观察性研究,纳入38例脑脊液NMDA受体IgG阳性的成人患者,使用线性和逻辑回归模型分析短期和长期随访的mRS和CASE结局。
主要发现
- 基线mRS中位数4(IQR 3-5),CASE均值12.9(SD 7.2)。
- 短期随访(中位10周,IQR 6-17)时,与较高CASE和mRS相关的因素包括自主神经功能障碍、昏迷/嗜睡、癫痫发作/癫痫持续状态和重症监护室入住(p<0.05)。
- 长期随访(中位70周,IQR 51-174)时,mRS中位数2(IQR 1-3),CASE均值4.4(SD 4.2)。
- 仅起病时乏力预测较高mRS评分(OR=5.6,95%CI 1.02-30.9,p=0.047)。
- 尽管mRS和CASE较基线改善(p<0.001),仅9例(31%)恢复至病前功能;超过6个月评估的患者中,中重度认知障碍42%、抑郁28%、焦虑30%。
临床怎么用
- 作者认为需要增加使用更细致的认知和情绪结局量表,以全面评估抗NMDA受体脑炎患者的长期功能损害。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Longitudinal outcomes in anti-NMDA receptor encephalitis (anti-NMDARe) are still not fully understood and may not be adequately captured with the modified Rankin Scale (mRS), often the sole reported outcome. We aim to characterize longitudinal outcomes in anti-NMDARe using multiple outcome measures. METHODS: This single-center, retrospective, observational study examined outcome measures (mRS and Clinical Assessment Scale in Autoimmune Encephalitis [CASE]) in adults with NMDA receptor-IgG in CSF at short- and long-term follow-ups using linear and logistic regression modeling. Patients with evaluations for cognitive impairment (Montreal Cognitive Assessment/Mini-Mental State Examination), depression (Patient Health Questionnaire-9), and anxiety (General Anxiety Disorder-7) >6 months from symptom onset were correlated with final CASE scores. RESULTS: Thirty-eight patients (76% female, median disease onset age = 28 years, range = 1-75 years) were included. The majority received first-line immunosuppressants (97%) at a median of 3.9 weeks (interquartile range [IQR] = 2.1-9.7) from symptom onset and 68% received second-line therapies. At baseline, median/mean mRS and CASE were 4 (IQR = 3-5) and 12.9 (SD = 7.2), respectively. At short-term follow-up (median = 10 weeks, IQR = 6-17), factors associated with higher CASE and mRS included dysautonomia, coma/lethargy, seizures/status epilepticus, and intensive care unit admission (p < 0.05). At long-term follow-up (median = 70 weeks, IQR = 51-174), median/mean mRS and CASE were 2 (IQR = 1-3) and 4.4 (SD = 4.2), respectively. Only weakness at symptom onset predicted higher mRS scores (odds ratio = 5.6, 95% confidence interval 1.02-30.9, p = 0.047). Despite both mRS and CASE improving from baseline (p < 0.001), only 9 patients (31%) returned to their premorbid function. Among patients with cognitive and mood evaluations >6 months from onset, moderate-severe cognitive impairment (42%), depression (28%), and anxiety (30%) were frequent. Cognitive and depression measures were associated with final CASE subscores (including memory, language, weakness, and psychiatric). DISCUSSION: Multiple clinical factors influenced short-term outcomes, but only onset weakness influenced long-term mRS, highlighting that mRS is predominantly affected by global motor function. Although mRS and CASE improved over time for most patients, these outcome measures did not capture the full extent of long-term functional impairment in terms of mood, cognition, and the ability to return to premorbid function. This emphasizes the need for increased utilization of more nuanced cognitive and mood outcome measures.
引用
- Morgan A, Li Y, Thompson NR, et al. Longitudinal Disability, Cognitive Impairment, and Mood Symptoms in Patients With Anti-NMDA Receptor Encephalitis. Neurology. 2024. PMID: 38266213. doi:10.1212/WNL.0000000000208019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。